Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 Dec 19;143(6):2170–2177. doi: 10.1016/j.jaci.2018.11.041

Figure 2.

Figure 2.

Summary of the proportion of patients receiving A. placebo (N=68) and B. mepolizumab (N=68) to meet each definition of clinical benefit.

1Remission category BVAS=0 and OGC dose ≤4 mg/day during the study treatment period; 2≥50% reduction in average OGC dose during Weeks 48–52; 3No EGPA relapses during the study treatment period.

BVAS; Birmingham Vasculitis Activity Score; OGC, oral glucocorticoid.